Castle Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-57.47	-67.14	-31.29	-10.28	2.99	-10.16	-15.31
Depreciation & Amortization	12.33	10.54	3.41	0.47	0.36	0.32	0.31
Share-Based Compensation	51.22	36.32	21.74	8.31	1.25	0.29	0.11
Other Operating Activities	-11.71	-21.38	-12.84	11.37	0.13	-6.55	-0.28
Operating Cash Flow	-5.63	-41.66	-18.98	9.87	7.02	-12.3	-12.23
Operating Cash Flow Growth	-	-	-	40.63%	-	-	-
Capital Expenditures	-13.61	-5.44	-3.47	-4.75	-0.94	-0.28	-0.49
Acquisitions	0	-26.42	-63.18	0	0	0	0
Change in Investments	-2.58	-134.69	0	0	0	0	0
Investing Cash Flow	-16.18	-166.55	-66.66	-4.75	-0.94	-0.28	-0.49
Share Issuance / Repurchase	2.98	3.33	6.21	333.25	67.32	0.04	0
Debt Issued / Paid	-0.14	-0.12	-0.01	-27.36	20.92	5.42	8.57
Other Financing Activities	-5.13	-1.69	-0.78	-	0.05	10.38	0.29
Financing Cash Flow	-2.3	1.52	5.42	305.89	88.29	15.84	8.87
Net Cash Flow	-24.11	-206.69	-80.22	311.01	94.37	3.27	-3.86
Free Cash Flow	-19.23	-47.09	-22.46	5.12	6.08	-12.57	-12.73
Free Cash Flow Growth	-	-	-	-15.81%	-	-	-
Free Cash Flow Margin	-8.75%	-34.36%	-23.87%	8.17%	11.72%	-55.17%	-92.54%
Free Cash Flow Per Share	-0.72	-1.81	-0.89	0.27	0.71	-6.60	-6.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).